Inhibikase Therapeutics Inc. (IKT) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Inhibikase Therapeutics I...

    NASDAQ: IKT · Real-Time Price · USD
    1.71
    -0.02 (-1.16%)
    At close: Sep 04, 2025, 3:59 PM

    Inhibikase Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a 260.5K 123.44K 3.1M
    Cost of Revenue
    		 26.27K 13.62M 6.72K 11.36M
    Gross Profit
    		 -26.27K -13.36M 116.72K -8.26M
    Operating Income
    		 -28.59M -20.09M -18.13M -14.77M
    Interest Income
    		 1.07M 1.06M 74.45K 19.92K
    Pretax Income
    		 -27.52M -19.03M -18.05M -14.79M
    Net Income
    		 -27.52M -19.03M -17.91M -14.81M
    Selling & General & Admin
    		 11.38M 6.73M 6.22M 6.51M
    Research & Development
    		 17.21M 13.62M 12.03M 11.36M
    Other Expenses
    		 -26.27K -13.62M -123.44K -3.1M
    Operating Expenses
    		 28.56M 6.73M 18.13M 14.77M
    Interest Expense
    		 n/a n/a 74.45K 19.92K
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 28.59M 20.35M 18.13M 14.77M
    Income Tax Expense
    		 n/a n/a -148.91K 19.92K
    Shares Outstanding (Basic)
    		 23.71M 5.33M 4.2M 3.03M
    Shares Outstanding (Diluted)
    		 23.71M 5.33M 4.2M 3.03M
    EPS (Basic)
    		 -1.16 -3.57 -4.26 -4.88
    EPS (Diluted)
    		 -1.16 -3.57 -4.26 -4.88
    EBITDA
    		 -27.49M -19.91M -18.12M -14.77M
    EBIT
    		 -27.52M -20.09M -18.13M -14.77M
    Depreciation & Amortization
    		 26.27K 177.4K 6.72K 14.77M

    Add to Watchlist